Pharmafile Logo
Pharmafocus logo
Advanced Search

Future of new AZ asthma drug uncertain after phase III failure

pharmafile | February 25, 2009 | News story | Research and Development |  AZ, respiratory 

Related Content

Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …

pharmafile_autumn_2020_front_cover

The Autumn 2020 edition of Pharmafile is available to read for free online now!

The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 …

1200px-astrazeneca_hq_in_cambridge_uk

AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients

AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised …

The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025